AWM Investment Company Inc. Raises Position in OPKO Health, Inc. $OPK

Key Points

• AWM Investment Company Inc. increased its stake in OPKO Health by 42.3% in Q1 2023, acquiring an additional 550,000 shares to own a total of 1,850,000 shares worth approximately $3.07 million.
• CEO Phillip Frost purchased 675,000 shares at an average price of $1.32, increasing his ownership by 0.32% to a total of around 214.68 million shares valued at $283.37 million.
• OPKO Health reported a loss per share of $0.19 for the last quarter, which was below analysts' expectations, and its revenue decreased by 13.9% year-over-year.

AWM Investment Company Inc. boosted its holdings in OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 42.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,850,000 shares of the biotechnology company's stock after buying an additional 550,000 shares during the period. AWM Investment Company Inc. owned approximately 0.23% of OPKO Health worth $3,071,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. Oak Thistle LLC acquired a new stake in shares of OPKO Health during the 1st quarter worth approximately $26,000. GM Advisory Group LLC acquired a new stake in shares of OPKO Health during the 1st quarter worth approximately $33,000. Cerity Partners LLC acquired a new stake in shares of OPKO Health during the 1st quarter worth approximately $36,000. Wealth Enhancement Advisory Services LLC boosted its stake in OPKO Health by 75.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after buying an additional 12,417 shares in the last quarter. Finally, Pallas Capital Advisors LLC acquired a new stake in OPKO Health in the 1st quarter valued at $43,000. 64.63% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on OPK. Zacks Research raised OPKO Health from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. LADENBURG THALM/SH SH raised OPKO Health to a "strong-buy" rating in a research note on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $2.75.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost bought 675,000 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $1.32 per share, with a total value of $891,000.00. Following the transaction, the chief executive officer directly owned 214,676,448 shares of the company's stock, valued at approximately $283,372,911.36. This represents a 0.32% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 49.69% of the company's stock.

OPKO Health Trading Up 2.6%

NASDAQ OPK traded up $0.04 on Monday, reaching $1.39. The company had a trading volume of 854,126 shares, compared to its average volume of 3,677,432. The stock's 50 day moving average is $1.35 and its 200-day moving average is $1.44. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -5.54 and a beta of 1.40. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. OPKO Health, Inc. has a 52 week low of $1.11 and a 52 week high of $2.04.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The business had revenue of $156.80 million during the quarter, compared to the consensus estimate of $165.74 million. OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. OPKO Health's quarterly revenue was down 13.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.01) EPS. Equities analysts predict that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.